Labetuzumab (Anti-CEACAM5 / CEA / CD66e) | Read Reviews & Product Use Citations

Labetuzumab (Anti-CEACAM5 / CEA / CD66e) is a humanised monoclonal antibody targeting carcinoembryonic antigen (CEA). It inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy. MW :145.36 KD.

Purity & Quality Control

Batch: A263801 Purity: 99% Protein concentration: 3.25mg/ml Endotoxin Level: ＜1EU/mg

99

Biological Activity

Description	Labetuzumab (Anti-CEACAM5 / CEA / CD66e) is a humanised monoclonal antibody targeting carcinoembryonic antigen (CEA). It inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy. MW :145.36 KD.

References
[1] Stein R, et al. Mol Cancer Ther. 2004 Dec;3(12):1559-64.

References

[1] Stein R, et al. Mol Cancer Ther. 2004 Dec;3(12):1559-64.

Product Details

CAS No.	219649-07-7
Molecular Weight	145.36
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field